Fig 1.
Choroidal thickness and pachyvessel diameter measurement on spectral domain (SD) optical coherence tomography with enhanced depth imaging (EDI) mode.
Choroidal thickness (yellow line) was obtained by measuring the perpendicular distance from the outer layer of the RPE to the inner surface of the sclera at the subfoveal area using software calipers. Pachyvessel diameter (green line) was obtained by measuring the vertical diameter of the largest outer choroidal vessel in the foveal area using software calipers.
Table 1.
Baseline characteristics of Group 1 (CSC with CNV), and Group 2 (CSC without CNV).
Table 2.
Visual and anatomical outcomes of both groups before and 1 month after treatment.
Fig 2.
Representative images of chronic central serous chorioretinopathy (CSC) with choroidal neovascularization (CNV) (Group 1).
The upper row: before treatment (A) Horizontal B-scan of optical corerence tomography (OCT) centered to the fovea showing subretinal fluid (SRF) with pigment epithelial detachment (PED). (B) Enface OCT angiography (2.9 x 2.9mm) through the choriocapillaris shows CNV below the PED. The lower row: 1 month after intravitreal injection of bevacizumab (IVB). (C) Shows complete resolution of SRF. (D) Shows a smaller area of the CNV with reduction of the dense microvasculature.
Table 3.
Effects of intravitreal bevacizumab injection in both groups.
Table 4.
Univariate and multivariate linear mixed models for associations between various clinical parameters and visual outcome after treatment in Group 1 (CSC with CNV).